Free to follow every thread. No paywall, no dead ends.
Breast cancer: the story on HearLore | HearLore
Breast cancer
The oldest known evidence of breast cancer dates back 4200 years to the Sixth Dynasty of Egypt, yet for millennia, the disease remained a terrifying mystery that ancient physicians could only describe as untreatable. The Edwin Smith Papyrus, one of the oldest medical texts in existence, documents eight cases of breast tumors and ulcers treated by cauterization, concluding with the stark, final verdict that there is no treatment. For centuries, the disease was viewed through the lens of humoralism, where doctors believed an excess of black bile caused the malignancy, or worse, that it was divine punishment for moral failings. Women suffered in silence, often dying in agonizing pain from fungating lesions that broke through the skin and wept fetid fluid, while physicians offered only detox purges, bloodletting, and arsenic ointments. Even when surgery was attempted in the 17th century, the lack of anesthesia and antiseptics made the procedure a death sentence for many, with records showing that out of 12 mastectomies performed by Richard Wiseman, eight patients died shortly after the operation from progressive cancer and only two were cured. The fear was so profound that breast cancer was discussed in hushed tones, and women tended to suffer silently rather than seeking care because the available treatments were more dangerous than the disease itself.
The Halsted Revolution
In 1882, William Stewart Halsted changed the trajectory of cancer treatment by introducing the radical mastectomy, a procedure that involved removing the entire breast, the underlying chest muscles, and the associated lymph nodes in the armpit. Before Halsted, 20-year survival rates for breast cancer were a dismal 10%, but his aggressive surgical approach raised that rate to 50%, establishing a new standard of care that would dominate American medicine for nearly a century. Halsted's theory was that cancer spread in a linear fashion from the breast to the lymph nodes and then to the rest of the body, so removing everything in the path of this spread was necessary to save lives. This radical approach often led to long-term pain and disability, with women left with disfigured chests and limited arm movement, yet it was seen as the only way to prevent recurrence. The procedure remained the standard of care in the United States until the 1970s, while Europe had already begun adopting breast-sparing procedures in the 1950s. The Halsted era was defined by a belief that the more tissue removed, the better the outcome, a philosophy that persisted until the 1960s when ten-year survival rates proved equal to less-damaging radical mastectomies. The turning point came with the work of George Crile Jr., who published Cancer and Common Sense in 1955, arguing that patients needed to understand their options, and later challenged the Halsted radical mastectomy in 1973, paving the way for a new understanding of metastasis as a systemic illness rather than a localized one.
When was the oldest known evidence of breast cancer discovered?
The oldest known evidence of breast cancer dates back 4200 years to the Sixth Dynasty of Egypt. The Edwin Smith Papyrus documents eight cases of breast tumors and ulcers treated by cauterization with the verdict that there is no treatment.
Who introduced the radical mastectomy for breast cancer treatment?
William Stewart Halsted introduced the radical mastectomy in 1882. This procedure involved removing the entire breast, the underlying chest muscles, and the associated lymph nodes in the armpit.
When was the pink ribbon launched as a symbol of breast cancer awareness?
The pink ribbon was launched in the 1990s by US-based corporations as part of cause-related marketing campaigns. Companies donated to breast cancer initiatives for every pink ribbon product purchased.
What is the lifetime risk of developing breast cancer for women with BRCA1 or BRCA2 genes?
Women with pathogenic variants in either of these genes face a 70% chance of developing breast cancer in their lifetime. They also face an approximately 33% chance of developing ovarian cancer.
When did hormone replacement therapy reports prove it increases breast cancer risk?
The 1995 reports from the Nurses Health Study and the 2002 conclusions of the Women Health Initiative trial proved that hormone replacement therapy significantly increased the incidence of breast cancer. Combined progesterone and estrogen therapy approximately doubles one's risk after 6 to 7 years of treatment.
What is the five-year survival rate for breast cancer in India compared to the United States?
In the United States, more than 90% of women survive breast cancer for at least five years from diagnosis. In India, this figure falls to 66%.
The pink ribbon, now the most prominent symbol of breast cancer awareness, was launched in the 1990s by US-based corporations as part of cause-related marketing campaigns, where companies donated to breast cancer initiatives for every pink ribbon product purchased. While these campaigns successfully raised billions of dollars and normalized the conversation around the disease, they also sparked a fierce debate about the commodification of suffering and the phenomenon known as pinkwashing. Critics like Samantha King and Barbara Ehrenreich argued that breast cancer culture had transformed from a serious individual tragedy into a market-driven industry of survivorship, where the primary goal was to maintain the disease's dominance as the pre-eminent women's health issue. The pink ribbon was criticized as a form of slacktivism that distracted society from the lack of progress on preventing and curing the disease, and as hypocrisy because some organizations wore the ribbon while selling products that increased cancer risk, such as alcoholic beverages. The culture demanded that women with breast cancer normalize and feminize their appearance, minimizing the disruption their illness caused to others, while anger, sadness, and negativity were silenced to fit the mold of the ideal survivor. This cultural shift, while raising awareness, also reinforced gender stereotypes and objectified women, turning their bodies into symbols of corporate philanthropy rather than focusing on the systemic issues of healthcare access and prevention.
The Genetic Lottery
While most breast cancers are sporadic, about 10% of cases result from inherited genetic predispositions, with the BRCA1 and BRCA2 genes being the most well-known variants. Women with pathogenic variants in either of these genes face a 70% chance of developing breast cancer in their lifetime, along with an approximately 33% chance of developing ovarian cancer. The discovery of these genes has led to a new era of preventive medicine, where women with high genetic risk can opt for preventive mastectomy, a procedure that reduces the risk of developing breast cancer by more than 95%. However, the average waiting time for this surgery is two years, which is much longer than recommended, leaving many women in a state of limbo. The genetic landscape of breast cancer is complex, with other tumor suppressor genes like p53, PTEN, and PALB2 also playing critical roles in increasing risk. For instance, variants in PALB2 increase the risk of developing breast cancer by around 50%, while mutations in p53 cause Li-Fraumeni syndrome. The genetic testing revolution has also highlighted disparities in research, as less than 3% of patients in clinical trials identify as Black, despite representing 12.7% of the national population, leading to treatments that may not be as effective for diverse populations. The genetic understanding of breast cancer has also revealed that triple-negative breast cancer, which lacks estrogen, progesterone, and HER2 receptors, is more common in younger Black or Hispanic women, creating a unique challenge for treatment and prognosis.
The Hormone War
The relationship between hormones and breast cancer is a complex dance of risk and protection, where factors like early menstruation, late menopause, and hormone replacement therapy can significantly increase the likelihood of developing the disease. Up to 80% of the variation in breast cancer frequency across countries is due to differences in reproductive history that impact a woman's levels of female sex hormones, particularly estrogen. Women who begin menstruating before age 12 or undergo menopause after age 51 are at increased risk, while those who give birth early in life are protected, with someone who gives birth as a teenager having around a 70% lower risk of developing breast cancer than someone who does not have children. The use of hormone replacement therapy for menopause symptoms can also increase a woman's risk, with combined progesterone/estrogen therapy approximately doubling one's risk after 6 to 7 years of treatment. The 1995 reports from the Nurses' Health Study and the 2002 conclusions of the Women's Health Initiative trial conclusively proved that hormone replacement therapy significantly increased the incidence of breast cancer, leading to a major shift in medical practice. Conversely, breastfeeding reduces one's chance of developing breast cancer, with an approximately 4% reduction in risk for every 12 months of breastfeeding experience. The hormonal landscape of breast cancer has also led to the development of targeted therapies, such as tamoxifen and aromatase inhibitors, which block the estrogen receptors that hormone receptor-positive breast cancers require to survive, reducing the risk of breast cancer death by around 40% over the next ten years.
The Survival Divide
Despite the global progress in breast cancer treatment, a stark divide exists between wealthy and developing nations, where survival rates vary dramatically based on access to screening and care. In the United States, UK, South Korea, Japan, and Australia, more than 90% of women survive breast cancer for at least five years from diagnosis, while in China, this figure drops to 82%, and in India, it falls to 66%. The incidence of breast cancer is rising by around 3% per year as populations in many countries get older, but the death rates are disproportionately higher in lower-income countries, where 1 in 48 women die of the disease compared to 1 in 71 in wealthy countries. This disparity is not just a matter of wealth but also of race and ethnicity, as Black women in the United States are more likely to die of breast cancer than white women, despite having lower incidence rates in some age groups. The median age of diagnosis for Black women is 59, compared to 62 in white women, and the five-year survival rate is 81% in Black women versus 92% in white women. Socioeconomic determinants, including poverty, culture, and social injustice, contribute to these disparities, with low-income, immigrant, disabled, and racial and sexual minority women being less likely to undergo breast cancer screening and thus more likely to receive late-stage diagnoses. The lack of representation in clinical trials, where less than 3% of patients identify as Black, further exacerbates the problem, as treatments designed based on research with diverse patient representation are not being developed for these populations.
The Future of Fighting
The landscape of breast cancer treatment is rapidly evolving, with new therapies targeting specific genetic mutations and immune system pathways offering hope where traditional chemotherapy has failed. For tumors that are HER2-positive, adding the HER2-targeted antibody trastuzumab to chemotherapy reduces the chance of cancer recurrence and death by at least a third, while newer drugs like pertuzumab and trastuzumab emtansine further enhance treatment efficacy. The development of PARP inhibitors for those with mutations that inactivate BRCA1 or BRCA2, and the use of immune checkpoint inhibitors like pembrolizumab for tumors with mutations in various DNA repair pathways, represent a new era of precision medicine. In 2025, Imlunestrant was approved for medical use in the United States, adding another tool to the arsenal against hormone receptor-positive breast cancer. The field is also exploring the use of cryoablation as a substitute for lumpectomy in small cancers, and investigating the potential of cancer vaccines and oncolytic virotherapy. Despite these advances, challenges remain, such as the need for more diverse participation in clinical trials and the development of treatments for triple-negative breast cancer, which remains particularly aggressive and has a relatively poor prognosis. The future of breast cancer treatment lies in the integration of genetic profiling, targeted therapies, and immunotherapy, offering a more personalized approach to care that addresses the unique characteristics of each patient's disease.